Global Metoprolol Succinates Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Extended-Release Tablets, Capsules, and Others), By Application (Hypertension, Angina, Heart Failure, and Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Metoprolol Succinate Market Insights Forecasts to 2035

• The Global Metoprolol Succinate Market Size Was Estimated at USD 379.84 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 6.68% from 2025 to 2035
• The Worldwide Metoprolol Succinate Market Size is Expected to Reach USD 773.47 Million by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Spherical Insights and Consulting, The Global Metoprolol Succinate Market Size was worth around USD 379.84 Million in 2024 and is predicted to grow to around USD 773.47 Million by 2035 with a compound annual growth rate (CAGR) of 6.68% from 2025 to 2035. The metoprolol succinate market is growing due to the growing number of cardiovascular diseases, mounting geriatric population, and rising awareness towards hypertension treatment. Technological innovations in drug formulation, developing healthcare infrastructure, and easier access to generic drugs also go a long way in the positive growth of the market globally.

Global Metoprolol Succinate Market Forecast and Revenue Outlook

• 2024 Market Size: USD 379.84 Million
• 2035 Projected Market Size: USD 773.47 Million
• CAGR (2025-2035): 6.68%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Market Overview

The market for metoprolol succinate refers to manufacturing and distributing a beta-1 selective adrenoceptor blocking drug that is mainly used in treating hypertension, angina pectoris, and heart failure. Being an extended-release version of metoprolol, it provides improved compliance by patients with once-daily dosing. The market has been increasing continuously with the rise of cardiovascular diseases, an expanding aging population worldwide, and increased awareness regarding long-term cardiac treatment. Moreover, the emerging prevalence of lifestyle disorders such as obesity, diabetes, and stress has been one of the key drivers for the demand for effective antihypertensive agents such as metoprolol succinate.

Opportunities lie in the growth markets in which healthcare infrastructure is expanding on a massive scale and access to essential medicines is increasing. Additionally, increasing telemedicine and e-pharmacy websites have eased the accessibility of chronic medication for patients. Leading pharma majors such as AstraZeneca, Novartis, Teva Pharmaceuticals, and Mylan (Viatris) control the industry by offering branded and generic products of medicines in global markets. On June 24, the FDA announced that Granules, a Telangana, India-based firm, recalled over 33,000 bottles of metoprolol succinate. The recall was initially categorized as Class III, which meant the drug would not have adverse health impacts even though it was a violative product.

Key Market Insights

• North America is expected to account for the largest share in the metoprolol succinate market during the forecast period.
• In terms of product type, the extended-release tablets segment is projected to lead the metoprolol succinate market throughout the forecast period.
• In terms of application, the hypertension segment captured the largest portion of the market.

Metoprolol Succinate Market Trends

• The metoprolol succinate market is witnessing steady growth due to rising cardiovascular disease prevalence.
• Generic drug approvals are expanding market accessibility and competition.
• Increased demand for extended-release formulations is driving product innovation.
• Strategic collaborations among pharmaceutical companies are enhancing global distribution.
• Digital health platforms are improving patient adherence to hypertension treatments.

Report Coverage

This research report categorizes the metoprolol succinate market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the metoprolol succinate market. Recent market developments and competitive strategies, such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the metoprolol succinate market.

Driving factors

Increased cardiovascular disease, an aging population, heightened hypertension awareness, increased generic availability, and government healthcare programs are the major drivers for the metoprolol succinate market. The increased incidence of cardiovascular diseases leads to the need for more efficient treatments. An ageing world population also plays a role, as older people are more prone to hypertension and heart disease. The increased availability of cheap generic options enhances access, with additional government-sponsored healthcare programs aimed at chronic disease management and affordable drug support continuing to drive the market higher.

As of July 31, 2025, the WHO reports cardiovascular diseases (CVDs) as the leading global cause of death, with 19.8 million deaths in 2022 (32% of all deaths). 85% were from heart attacks and strokes, mostly in low and middle income countries. CVDs caused 38% of premature noncommunicable disease deaths in 2021.

Restraining Factor

Side effects, stringent regulations, alternative treatments, patent losses, and price pressures restrain the growth of the metoprolol succinate market. Side effects restraining the market include the potential to decrease patient compliance. Stringent regulations enhance approval complexity and expenses. Alternative treatments provide competitive alternatives, whereas patent losses create generic competition. Further, price pressures constrain profit margins and market growth.

Market Segmentation 

The global metoprolol succinate market is divided into product type and application.

Global Metoprolol Succinate Market, By Product Type:

• The extended-release tablets segment dominated the market in 2024 and is projected to grow at a substantial CAGR of approximately 6.2% during the forecast period.  

Based on product type, the global metoprolol succinate market is segmented into extended-release tablets, capsules, and others. Among these, the extended-release tablets segment dominated the market in 2024 and is projected to grow at a substantial CAGR of approximately 6.2% during the forecast period. Extended-release tablets are more preferred for the treatment of cardiovascular diseases since they offer constant drug release, sustainable therapeutic levels, and enhanced convenience of dosing, which improves patient compliance, particularly for long-term illnesses such as hypertension and heart failure.

The capsules segment in the metoprolol succinate market is expected to grow at the fastest CAGR over the forecast period. Capsules are used in patients with difficulty swallowing tablets or where specialized preparations are required. Their convenience of flexible dosing and concurrent use with other cardiovascular drugs make them a convenient and useful choice for clinicians.

Global Metoprolol Succinate Market, By Application:

• The hypertension segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR of around 6. 5% during the forecast period.

Based on application, the global metoprolol succinate market is segmented into hypertension, angina, heart failure, and others. Among these, the hypertension segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR of around 6. 5% during the forecast period. Hypertension is the dominant application owing to its widespread prevalence worldwide. Sedentary lifestyles, unhealthy diets, and stress are among the factors that lead to its increase. Metoprolol Succinate effectively reduces blood pressure by reducing heart rate and cardiac workload, and thus becomes a must for hypertension control on a global basis.

The angina segment in the metoprolol succinate market is expected to grow at the fastest CAGR over the forecast period. Metoprolol succinate is effective in controlling angina by reducing myocardial oxygen demand, frequency, and severity of attacks. It enhances tolerance to exercise and relieves chest pain, maintaining high demand owing to its established safety and efficacy in the treatment of angina.

Regional Segment Analysis of the Global Metoprolol Succinate Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America Metoprolol Succinate Market Trends

North America is expected to hold the largest share of the global metoprolol succinate market over the forecast period.

The North American region is forecasted to account for the largest proportion of the global metoprolol succinate market throughout the forecast period, owing to a number of driving factors. The region has a high incidence rate of cardiovascular diseases and hypertension, fueling high demand for efficient treatment such as metoprolol succinate. Moreover, sophisticated healthcare infrastructure, extensive awareness, and effortless accessibility to healthcare services are some of the other factors driving the market forward. The availability of large pharmaceutical players and constant research and development ensures North America's market leadership further, contributing to about 35-40% of the world market share.

U.S. Metoprolol Succinate Market Trends

The U.S. metoprolol succinate market increases due to the large incidence of cardiovascular disease (such as hypertension and heart failure) and the population's growth due to an aging society that requires long-term treatments. Greater patient awareness and the generic option enhance affordability and accessibility, with the demand for this common beta-blocker increasing.

Asia Pacific Metoprolol Succinate Market Trends

Asia Pacific is expected to grow at the fastest CAGR in the metoprolol succinate market during the forecast period. Asia Pacific is anticipated to expand at the highest CAGR in the market for metoprolol succinate over the forecast period, attributed to the region's fast-growing elderly population and prevalence of cardiovascular diseases and hypertension are key factors driving increasing demand. Improvement in healthcare infrastructure, increased awareness regarding the management of chronic diseases, and rising government efforts toward making affordable medication available are impelling market growth. The presence of inexpensive generic medications also drives the adoption rate in emerging economies such as China and India. Thus, Asia Pacific is expected to account for the highest market share, which is estimated at approximately 25-30% by the end of the forecast period.

India Metoprolol Succinate Market Trends

Market growth for India's metoprolol succinate is fueled by the growing incidence of cardiovascular diseases (CVDs) and pressure for efficient, cost-effective therapies. Some of the principal market trends are the use of extended-release (ER) formulations for improved patient compliance and the greater availability of generic forms after patent expiration, which increases affordability and accessibility, especially in developing markets.

China Metoprolol Succinate Market Trends

China's metoprolol succinate market is expanding as a result of rising cardiovascular disease incidence and a sizable hypertensive patient base, driving drug demand. The nation commands a major market share as a leading manufacturer with pharmaceutical capacity growth and demand for extended-release formulations that enhance patient compliance.

Japan Metoprolol Succinate Market Trends

Japan's metoprolol succinate Market would be fueled by Japan's aging population and the growing number of cases of cardiovascular disease, specifically hypertension and chronic heart failure, which metoprolol succinate is well-suited to treat. These trends are ongoing expansion and a major contribution to the drug within the Japanese healthcare system.

Europe Metoprolol Succinate Market Trends

The European metoprolol succinate market is growing due to the rising prevalence of cardiovascular diseases and hypertension, increased healthcare expenditure, and growing awareness about chronic disease management. Additionally, supportive government policies, expanding generic drug availability, and advancements in pharmaceutical research contribute to market growth, positioning Europe as a significant player in the global market.

France Metoprolol Succinate Market Trends

The France metoprolol succinate market is experiencing growth due to a rising aging population, increasing incidence of hypertension, and strong public healthcare coverage, which ensures wider access to essential cardiovascular medications, including affordable generics.

U.K. Metoprolol Succinate Market Trends

The U.K. metoprolol succinate market is expanding with the growth in cardiovascular disease cases, awareness of hypertension, government healthcare provisions, and improved availability of low-cost generic drugs, which is enhancing treatment uptake.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global metoprolol succinate market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

Worldwide Top Key Players In The Metoprolol Succinate Market Include

• Dr. Reddy's Laboratories
• AstraZeneca
• Sun Pharmaceutical Industries Ltd.
• Lannett
• Granules India Limited
• Cipla Inc.
• Ipca Laboratories
• Novartis AG
• Alembic Pharmaceuticals
• Mylan N.V.
• Vasyo Industries Pvt. Ltd.
• Lupin Pharmaceuticals
• Others 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent development

• In August 2025, CDSCO’s Subject Expert Committee rejected AstraZeneca Pharma’s proposal to update the prescribing information for Seloken XL and requested a comparison with the approved PI in the USA and EU, along with justifications for the proposed changes.
• In July 2025, Granules India recalled over 33,000 bottles of Metoprolol Succinate in the U.S. after a batch failed dissolution tests. The Class II recall signals possible temporary or reversible health effects due to manufacturing issues.
• In August 2024, NPPA approved Sun Pharmaceuticals’ request to shift manufacturing of two telmisartan, chlorthalidone metoprolol succinate formulations to its Sikkim facility from Ravenbhel Healthcare, allowing continued marketing at approved prices as per its earlier decision on in-house manufacturing by marketing companies.
• In August 2023, Lupin Limited received U.S. FDA approval for its ANDA to market Metoprolol Succinate Extended-Release Tablets (25-200 mg), a generic version of Toprol XL. The approved product will be manufactured at Lupin’s Pithampur facility in India.
• In June 2023, Granules India received US FDA approval for its ANDA of Metoprolol Succinate ER Tablets (25–200 mg), bioequivalent to Toprol-XL. The tablets are indicated for treating hypertension to effectively lower blood pressure in patients.

Market Segment

This study forecasts revenue at the global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the metoprolol succinate market based on the following segments:

 Global Metoprolol Succinate Market, By Product Type

• Extended-Release Tablets
• Capsules
• Others

Global Metoprolol Succinate Market, By Application

• Hypertension
• Angina
• Heart Failure
• Others

Global Metoprolol Succinate Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa